Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases

Journal of Oral Pathology and Medicine

Volumn 34, Issue 2, 2005, Pages 120-123

  Bagan, Jose V ^a   Murillo, J ^a   Jimenez, Y ^a   Poveda, R ^a   Milian, M A ^a   Sanchis, J M ^a   Silvestre, F J ^b   Scully, C ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bisphosphonates; Cancer; Chemotherapy; Jaws; Osteonecrosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CLINDAMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; HORMONE ANTAGONIST; INTERFERON; LETROZOLE; MEGESTROL; MELPHALAN; METHOTREXATE; PAMIDRONIC ACID; TAMOXIFEN; THALIDOMIDE; ZOLEDRONIC ACID;

ABSCESS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AVASCULAR NECROSIS; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC OSTEOMYELITIS; CLINICAL ARTICLE; DEBRIDEMENT; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; JAW DISEASE; MALE; MANDIBLE; MAXILLA; MULTIPLE MYELOMA; PRIORITY JOURNAL; SKIN FISTULA; TOOTH EXTRACTION; TOOTH FISTULA;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS;

EID: 12444268934     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2004.00269.x     Document Type: Article

References (17)

1. Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 2003; 14: 213-25.
2. Reuther T, Schuster T, Mende U, Kubler A. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients - a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 2003; 32: 289-95.
3. Pogrel MA, Miller CE. A case of maxillary necrosis. J Oral Maxillofac Surg 2003; 61: 489-93.
4. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61: 1104-7.
5. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4.
6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7.
7. Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg 2003; 61: 60.
8. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004; 62: 391-2.
9. Assael LA. New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg 2004; 62: 125-6.
10. Ruggiero SL, Merotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34.
11. Gonzalez-Moles MA, Bagan-Sebastian JV. Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 2000; 29: 514-8.
12. Demerjian N, Bolla G, Spreux A. Severe oral ulcerations induced by alendronate. Clin Rheumatol 1999; 18: 349-50.
13. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-44.
14. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-61.
15. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003; 61: 1238-9.
16. Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 2002; 41: 346-7.
17. Astrand J, Aspenberg P. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord 2002; 3: 19.